Munich Cancer Registry



- Incidence and Mortality
- Selection Matrix
- Homepage
- Deutsch

ICD-10 D03: Melanoma in situ

1988-1997	1998-2014
366	4,702
373	4,896
298	3,569
04/11/2016	
12/23/2015	
4.64 m	
	366 373 298 04/11/2016 12/23/2015



Munich Cancer Registry at Munich Cancer Center Marchioninistr. 15 Munich, 81377 Germany

http://www.tumorregister-muenchen.de/en

 $http://www.tumorregister-muenchen.de/en/facts/surv/sD03_E-ICD-10-D03-Melanoma-in-situ-survival.pdf$

Survival




Figure 1a. Relative survival of patients with melanoma in situ by period of diagnosis. Included in the evaluation are 3,854 cases diagnosed between 1988 and 2014.

The survival results of the SEER program (Surveillance, Epidemiology, and End Results) of the American National Cancer Institute (NCI) are summarized as the period of diagnosis from 1998 to 2011, and are represented by gray diamonds in order to facilitate comparisons between MCR and SEER.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided populationbased statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

	F	Period	of diag	gnosis	;	
	1988-	1997	1998-	2006	200)7+
	n=2	297	n=1,	112	n=2,	,445
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0
1	99.0	99.9	99.4	100.0	99.4	100.0
2	97.2	99.9	98.5	100.0	98.3	100.0
3	95.1	99.9	97.9	100.0	97.4	100.0
4	93.3	99.8	96.1	100.0	95.2	100.0
5	92.6	99.8	94.7	100.0	94.2	100.0
6	90.8	99.8	93.2	100.0	93.1	100.0
7	90.1	99.8	90.9	100.0	90.6	100.0
8	88.3	99.8	89.3	100.0		
9	86.1	99.8	87.2	100.0		
10	85.0	99.8	85.8	100.0		
11	82.8	99.8	84.0	100.0		
12	81.0	99.8	82.0	100.0		
13	79.1	99.8	79.1	100.0		
14	76.8	99.0	78.2	100.0		
15	74.9	98.3	77.7	100.0		
16	73.3	97.4	76.0	99.7		
17	72.9	97.4				
18	71.6	97.4				
19	69.6	97.4				
20	68.2	97.4				

Table 1b. Observed (obs.) and relative (rel.) survival of patients with melanoma in situ by period of diagnosis for period 1988-2014 (N=3,854).






Figure 2a. Survival of patients with melanoma in situ by gender. Included in the evaluation are 3,854 cases diagnosed between 1988 and 2014.

Gender					
	Ma		Ferr	nale	
	n=1,	744	n=2,	110	
Years	obs. %	rel. %	obs. %	rel. %	
0	100.0	100.0	100.0	100.0	
1	99.3	100.0	99.5	100.0	
2	97.9	100.0	98.6	100.0	
3	96.5	100.0	98.0	100.0	
4	94.5	100.0	96.1	100.0	
5	93.1	100.0	95.2	100.0	
6	92.1	100.0	93.4	100.0	
7	89.3	100.0	92.0	100.0	
8	86.9	100.0	90.8	100.0	
9	85.0	100.0	88.4	100.0	
10	83.5	100.0	87.3	100.0	
11	81.8	100.0	85.3	100.0	
12	79.9	100.0	83.2	100.0	
13	76.7	100.0	81.4	99.5	
14	74.0	100.0	80.7	99.5	
15	72.5	100.0	79.4	99.5	
16	70.1	100.0	78.4	99.5	
17	68.5	100.0	78.4	99.5	
18	65.5	100.0	78.4	99.5	
19	63.2	100.0	76.5	99.5	
20	61.7	100.0	75.2	99.5	

Table 2b. Observed (obs.) and relative (rel.) survival of patients with melanoma in situ by gender for period 1988-2014 (N=3,854).




Figure 3a. Observed survival of patients with melanoma in situ by age category. Included in the evaluation are 3,854 cases diagnosed between 1988 and 2014.




Figure 3b. Relative survival of patients with melanoma in situ by age category. Included in the evaluation are 3,854 cases diagnosed between 1988 and 2014.

Age category										
		0-49	yrs	50-59	9 yrs	60-69	9 yrs	70+	yrs	
		n=1,	131	n=6	629	n=9	934	n=1,	160	
	Years	obs. %	rel. %							
	0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	
	1	100.0	100.0	99.8	100.0	99.5	100.0	98.4	100.0	
	2	100.0	100.0	99.1	100.0	98.9	100.0	95.6	100.0	
	3	100.0	100.0	99.1	100.0	98.5	100.0	92.8	100.0	
	4	100.0	100.0	98.9	100.0	97.3	100.0	87.3	100.0	
	5	99.8	100.0	98.7	100.0	97.1	100.0	83.5	100.0	
	6	99.1	100.0	98.0	100.0	96.2	100.0	80.2	100.0	
	7	99.1	100.0	97.7	100.0	93.8	100.0	74.6	100.0	
	8	98.9	100.0	96.6	100.0	92.6	100.0	69.4	100.0	
	9	98.9	100.0	95.8	100.0	91.2	100.0	62.1	100.0	
	10	98.9	100.0	95.4	100.0	89.6	100.0	58.4	100.0	
	11	98.9	100.0	94.9	100.0	87.5	100.0	52.2	100.0	
	12	98.9	100.0	93.6	100.0	84.9	100.0	46.5	100.0	
	13	98.9	100.0	93.0	100.0	82.4	100.0	37.4	98.0	
	14	98.9	100.0	92.1	100.0	79.2	100.0	33.6	96.5	
	15	98.2	100.0	92.1	100.0	76.6	100.0	30.2	96.5	
	16	98.2	100.0	91.1	100.0	71.7	100.0	27.2	95.4	
	17	98.2	100.0	91.1	100.0	69.8	100.0			
	18	98.2	100.0	89.4	100.0	67.1	100.0			
	19	98.2	100.0	87.4	100.0	63.6	100.0			
	20	98.2	100.0	87.4	100.0					

Table 3c. Observed (obs.) and relative (rel.) survival of patients with melanoma in situ by age category for period 1988-2014 (N=3,854).

Shortcuts

MCR	Munich Cancer Registry, Germany							
NCI SEER UICC	National Cancer Institute, USA Surveillance, Epidemiology, and End Results, USA Union for International Cancer Control, Geneva							
DCO NA NOS	Death certificate only Not available Not otherwise specified	Death certificate provides the only notification to the registry.						
OS	Overall/Observed survival	Overall/Observed survival (Kaplan-Meier estimate) Date of entry: diagnosis Event: death from any cause						
RS	Relative survival	Survival compared to "general population", ratio of observed to expected survival (Ederer II method), reflecting cancer specific survival						
AS	Assembled survival	Assembled chart of observed, expected, relative survival						
CS	Conditional survival	Survival probability under the condition of surviving a given period of time						
TTP	Time to progression	Time to first progression / relapse Date of entry: diagnosis Event: (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression						
	1-KM	1 minus Kaplan-Meier estimator ("inverse" Kaplan-Meier estimator)						
	CI	Cumulative incidence Death as competing risk (according to Kalbfleisch und Prentice)						
PPS	Post-progression survival	Survival since first progression / relapse (Kaplan-Meier estimate) Date of entry (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression Event: death from any cause						

Recommended Citation

Munich Cancer Registry. Survival ICD-10 D03: Melanoma in situ [Internet]. 2016 [updated 2016 Apr 11; cited 2016 Jun 1]. Available from: http://www.tumorregister-muenchen.de/en/facts/surv/sD03_E-ICD-10-D03-Melanoma-in-situ-survival.pdf

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

Index of figures and tables

Fig./Tbl.	Page
1a Relative survival by period of diagnosis (chart)	2
1b Survival by period of diagnosis (table)	3
2a Survival by gender (chart)	4
2b Survival by gender (table)	4
3a Observed survival by age category (chart)	5
3b Relative survival by age category (chart)	5
3c Survival by age category (table)	6